Fetal hemoglobin levels and morbidity in untransfused patients with &#946;-thalassemia intermedia by K.M. Musallam et al.
CLINICAL TRIALS AND OBSERVATIONS
Brief report
Fetal hemoglobin levels and morbidity in untransfused patients with
-thalassemia intermedia
Khaled M. Musallam,1 Vijay G. Sankaran,2 Maria Domenica Cappellini,1 Lorena Duca,1 David G. Nathan,2,3 and Ali T. Taher4
1Department of Medicine and Medical Specialties, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Ca’ Granda Foundation Maggiore Policlinico
Hospital, Milan, Italy; 2Department of Medicine, Children’s Hospital Boston, Boston, MA; 3Dana-Farber Cancer Institute, Boston, MA; and 4Department of Internal
Medicine, American University of Beirut Medical Center, Beirut, Lebanon
To evaluate the association between fetal
hemoglobin (HbF) levels and morbidity in
-thalassemia intermedia (TI), we ana-
lyzed data from 63 untransfused patients
who had also never received HbF induc-
tion therapy. Patient records were re-
viewed for any history of 10 predefined
morbidities. Laboratory measurements for
markers of ineffective erythropoiesis were
also obtained. The mean age of patients
was 32.1 years, 47.6% were males, and
the median HbF level was 37.2%. HbF
levels correlated positively with total he-
moglobin, yet negatively with growth dif-
ferentiation factor-15 and non–transferrin-
bound iron levels. Median HbF levels were
significantly lower in patients with the
majority of evaluated morbidities than in
those without. There was a strong nega-
tive adjusted linear correlation between
the HbF level and the total number of
morbidities (R 2  0.825, P < .001). The
HbF threshold of 63.7% had 95.5% sensi-
tivity and 100% specificity for ensuring
absence of morbidity. There exists a
strong association between HbF levels
and morbidity in the subset of untrans-
fused patients with TI. (Blood. 2012;
119(2):364-367)
Introduction
Patients with -thalassemia intermedia (TI) usually present to
medical attention after 2 years of age and maintain hemoglobin
values between 70 and 90 g/L without the need for a regular
transfusion regimen.1 Nonetheless, the diagnosis of TI can be
associated with a number of serious complications involving
several organ systems.1,2 Although the mechanisms underlying
the disease process have been studied extensively, our under-
standing of the risk factors that govern the clinical heterogeneity
of the disease remains limited, and only a few genetic and
environmental modifiers of disease severity have been eluci-
dated.1 Some of the variability in the observed morbidities in
this patient population has been attributed to the choice of
treatment approach, which in most instances does not follow
clear guidelines, in contrast to approaches used in patients with
-thalassemia major.2 Fetal hemoglobin (HbF) levels have been
shown to be an important modifier of morbidity and mortality in
adults with sickle cell disease.3-5 Furthermore, it is known that
patients with the same -thalassemia mutations are more likely
to have thalassemia major if they have lower production of
HbF.6 HbF is clearly an important contributor to the clinical
variability in -thalassemia; however, the extent to which
interindividual variation in HbF levels contributes to the clinical
heterogeneity observed in TI patients has never been evaluated.
Here, we examine the association between HbF levels and
morbidity in untransfused patients with TI. By selecting patients
who have never received transfusions or HbF induction therapy,
we could ensure that the effects seen were more likely to be
caused by the variation in HbF and not by other confounding
variables.
Methods
This was a cross-sectional study of all TI patients treated at 2 centers in
Milan, Italy, and Beirut, Lebanon (n  260). At both centers, an age of
diagnosis 2 years and hemoglobin values between 70 and 90 g/L without
the need for a regular transfusion regimen, with or without splenomegaly,
were the main criteria to define the TI phenotype on presentation.1 It should
be noted, however, that TI patients may have changes in the total
hemoglobin level as they grow, and some patients may eventually require
transfusion therapy.1 After the exclusion of all patients with any history of
blood transfusion, iron chelation, or HbF induction therapy, 63 patients
were available for analysis. The current study utilized a completely
de-identified dataset. Data was collected as part of now completed clinical
studies, and which were approved by the Institutional Review Board at both
institutions. All patients had signed an informed consent form for participat-
ing in the original studies in accordance with the Declaration of Helsinki.
By review of genetic records, none of the patients had coinheritance of
-thalassemia ( [3.7 and 4.2] or 0 [Med and SEA]) or
determinants associated with increased -globin chain production (Xmn-I
/ genotype at position 158 of HG2). -Globin and -globin
genotypes of the study sample are described in supplemental Table 1
(available on the Blood Web site; see the Supplemental Materials link at the
top of the online article). None of the patients had hemoglobin S, C,
E/-thalassemia, or -thalassemia. Medical charts were reviewed to
retrieve data on demographics (age and sex), splenectomy status, and
presence of morbidities relevant in patients with TI1 (extramedullary
hematopoiesis, pulmonary hypertension, venous thromboembolism, heart
failure, leg ulcers, abnormal liver function, diabetes mellitus, hypothyroid-
ism, hypogonadism, and osteoporosis), defined according to criteria
described in the OPTIMAL CARE study.2 Patients were also assigned a
morbidity score, which was the total number of morbidities experienced up
to the time of study. For each patient, we also retrieved the HbF level
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determined at the time of diagnosis (measured at a median age of 9 years,
range 5-21 years; the date of measurement preceded the dates of splenec-
tomy, other laboratory measurements, and morbidity occurrence). Without
intervention, HbF levels are thought to remain stable throughout the course
of the disease. To adjust for the confounding effect of ineffective
erythropoiesis on any observed association, we also retrieved data on the
following relevant laboratory indices from all available laboratory records:
mean total hemoglobin, nucleated red blood cells, growth differentiation
factor (GDF)–15, serum ferritin, and non–transferrin-bound iron (NTBI)
levels. In both centers, GDF-15 and NTBI levels were determined as
described elsewhere.7,8
Statistical analysis
Data are described as mean 	 SD, median (interquartile range), or
percentage. Bivariate correlations to determine the association between
HbF levels and study parameters were conducted with the Mann-Whitney
U test for categorical variables and the Spearman correlation coefficient for
continuous variables. Linear regression analysis, with adjustment for
clinically relevant variables, was used to evaluate the independent correla-
tion between HbF levels and the occurrence of morbidity. Receiver
operating characteristic curve analysis was used to determine the HbF level
threshold with the highest sum of sensitivity and specificity to discriminate
patients who experienced morbidity from those who did not. All P values
were 2 sided, with the level of significance set at
 .05.
Results and discussion
The mean age of patients in the present study was 32.1 	 16.2
years (range 8-78 years). A total of 30 patients (47.6%) were
males, and 37 (58.7%) were splenectomized. The mean total
hemoglobin level was 89.0 	 16.1 g/L (range 57-131 g/L), and
the median HbF level was 37.2% (interquartile range 57.8%,
range 1.1%-100%). Bivariate correlations between HbF level
and study parameters are summarized in Table 1. Clinical and
laboratory quantification of the severity of ineffective erythropoi-
esis remains a challenge. Ineffective erythropoiesis is the
hallmark of the disease process in TI, leading to anemia,
hemolysis, and iron overload because of excessive intestinal
absorption.1,9 Measurement of GDF-15, a member of the
transforming growth factor- superfamily, is thought to indicate
the extent of ineffective erythropoiesis.10 NTBI levels are
thought to reflect the erythropoietic rate and are increased by
ineffective erythropoiesis.11,12 The negative correlation between
HbF levels and both of these markers in the present report, as
well as the positive correlation with total hemoglobin levels,
suggests an ameliorating role of HbF level on the severity of
ineffective erythropoiesis, probably through an effect on globin
chain imbalance. Previous work on small cohorts of TI patients
showed that high levels of circulating HbF ( 40%) could be
associated with higher erythropoietin activity and expansion of
erythropoiesis.13,14 The present study suggests that this increase
in erythropoietic drive is also less “ineffective.” The exact
mechanisms that could explain such an association, however,
merit further investigation.
A total of 41 patients (65.1%) experienced at least 1 morbidity,
and 30 patients (47.6%) experienced multiple morbidities. The
median HbF level was significantly lower in patients with the
majority of evaluated morbidities than in those without (Table 1).
On linear regression analysis, and after adjustment for age,
splenectomy, total hemoglobin, nucleated red blood cells, GDF-15,
serum ferritin, and NTBI levels, there was a strong negative linear
correlation between HbF level and the morbidity score ( 0.050,
95% confidence interval [CI] 0.059 to 0.042; R2  0.825,
P 
 .001; Figure 1A). These results remained unchanged when the
analysis was stratified for splenectomized and nonsplenectomized
patients (splenectomized: beta0.053, 95% CI0.063 to0.042,
R2  0.785, P 
 .001; nonsplenectomized: beta 0.045, 95% CI
0.060 to 0.030, R2  0.852, P 
 .001). A regression analysis
was also performed with the total HbF level in grams per liter rather
than the % HbF, and the results remained essentially unchanged
(beta 0.040, 95% CI 0.048 to 0.033, R2  0.882, P 
 .001).
An even stronger correlation was found using the log of the % HbF
(beta 3.401, 95% CI 3.915 to 2.886, R2  0.933, P 
 .001;
Figure 1B). The HbF threshold 63.7% had 95.5% sensitivity and
100% specificity for ensuring absence of morbidity on receiver
Table 1. Bivariate correlations between fetal hemoglobin level and
study parameters
Parameter Value P
Age (y) rs 0.164 .199
Sex
Male (n  30) 37 (54)
.625Female (n  33) 42.3 (62.4)
Splenectomy
No (n  26) 18.5 (51)
.007Yes (n  37) 47.3 (51.4)
Total hemoglobin level (g/L) rs 0.595 
 .001
NRBC count ( 106/L) rs 0.073 .567
GDF-15 level (pg/mL) rs 0.522 
 .001
Serum ferritin level (g/L) rs 0.092 .471
NTBI level (mol/L) rs 0.444 
 .001
Morbidities
Extramedullary hematopoiesis
No (n  50) 50.2 (59.8)
.003Yes (n  13) 18.8 (31.1)
Pulmonary hypertension
No (n  44) 58.8 (56.6)

 .001Yes (n  19) 8.7 (25.9)
Venous thromboembolism
No (n  51) 47.3 (57.1)
.003Yes (n  12) 18.1 (17.8)
Heart failure
No (n  57) 43.3 (56.2)
.002Yes (n  6) 4.4 (8.5)
Leg ulcers
No (n  52) 45.0 (57.4)
.002Yes (n  11) 10.5 (24.9)
Abnormal liver function
No (n  49) 55.5 (55.2)

 .001Yes (n  14) 13.9 (20.1)
Diabetes mellitus
No (n  60) 40.6 (60.4)
.309Yes (n  3) 22.8 (0.5)
Hypothyroidism
No (n  53) 47.3 (56.3)

 .001Yes (n  10) 5.5 (15.0)
Hypogonadism
No (n  53)* 49.3 (49.7)

 .001Yes (n  8) 8.1 (8.6)
Osteoporosis
No (n  49) 55.5 (57.0)

 .001Yes (n  14) 9.6 (18.5)
Data are presented as median fetal hemoglobin in % (interquartile range) unless
otherwise indicated.
NRBC indicates nucleated red blood cell; GDF, growth differentiation factor;
NTBI, non–transferrin-bound iron; and rs, Spearman correlation coefficient.
*Two patients were younger than the age-appropriate criteria to define
hypogonadism.
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operating characteristic curve analysis (area under the curve 0.986,
95% CI 0.957 to 1.000).
We were able to demonstrate here the quantitative ameliorating
effect of HbF levels on morbidity in TI. Although we included a
select group of TI patients not receiving transfusion or HbF
induction therapy in the present study, we believe that our results
will be more broadly applicable in TI. Despite the observation of a
statistically independent effect of HbF levels on morbidity, these
increased levels could still be acting to reduce the extent of
ineffective erythropoiesis and increase total hemoglobin levels in
the patients with TI. The mechanisms underlying these observa-
tions should be the target of future studies.
In the absence of intervention, the heterogeneity of HbF levels
in these patients may be rooted at the molecular level. Recent
genome-wide association studies have identified 3 loci (at BCL11A,
HBS1L-MYB, and the -globin locus) that carry DNA polymor-
phisms that modulate HbF levels.15-19 These polymorphisms have
been associated with higher levels of HbF in patients with sickle
cell disease and were shown to correlate with a milder disease
course.16,18,19 They were found to occur at higher frequencies in
patients with TI than in patients with -thalassemia major6,16,20 and
were associated with milder disease severity in patients with
hemoglobin E/-thalassemia.21 Whether these polymorphisms ex-
plain the spectrum of HbF levels and associated morbidity in TI
patients will need to be explored in future studies.
In conclusion, the present study demonstrates that high HbF levels
are associated with a milder disease course in patients with TI. The
mechanisms underlying this observation should be evaluated in view of
the recent advances in understanding HbF expression and could lead to
potential therapeutic interventions.22 Furthermore, our demonstration
that the amelioration in the extent of morbidity is quantitatively
associated with HbF levels suggests that therapeutic efforts aimed at
even modest induction of these levels may have a profound effect on
disease course in patients with TI.
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Figure 1. Association between fetal hemoglobin level and the morbidity score. Figures show linear regression of (A) fetal hemoglobin level and (B) log fetal hemoglobin
level against the morbidity score. Tables represent results of linear regression analysis after adjustment for indicated variables. NRBC indicates nucleated red blood cell; GDF,
growth differentiation factor; NTBI, non–transferrin-bound iron; and CI, confidence interval.
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